Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 testing for breast cancer patients: is there more to the story?

Oncology (Williston Park, N.Y.) - 1 Dec 2009

Henry N Lynn, Hayes Daniel F, Rae James M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Breast Neoplasms
Share to Chemotherapy, Adjuvant
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Medication Adherence

Share to Precision Medicine

Share to Selective Estrogen Receptor Modulators

Share to Tamoxifen

Source

Identifiers

PMID: 20120836

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 testing for breast cancer patients: is there more to the story?PMID 20120836Read ↗

Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.Semantic proximity Read ↗

CYP2D6 testing in breast cancer: ready for prime time?Semantic proximity Read ↗

Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

CYP2D6 and Tamoxifen: Lessons Learned.Semantic proximity Read ↗

One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Clinical and Pharmacogenomic Predictors of Survival in Tamoxifen Treated Breast Cancer Female Patients: A Real-World StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.